2019 Q1 Form 10-K Financial Statement
#000156459019008830 Filed on March 22, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q4 | 2018 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | $900.0K | ||
| YoY Change | |||
| Gross Profit | -$900.0K | ||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.930M | $2.150M | $10.20M |
| YoY Change | 4.27% | -19.48% | 8.74% |
| % of Gross Profit | |||
| Research & Development | $3.793M | $3.330M | $10.32M |
| YoY Change | 15.43% | -1.19% | -33.69% |
| % of Gross Profit | |||
| Depreciation & Amortization | $14.60K | $90.00K | $49.62K |
| YoY Change | -91.51% | -74.29% | -96.77% |
| % of Gross Profit | |||
| Operating Expenses | $4.841M | $5.470M | $16.14M |
| YoY Change | -20.55% | -9.29% | -35.31% |
| Operating Profit | -$4.841M | -$16.14M | |
| YoY Change | -20.55% | -35.31% | |
| Interest Expense | $695.5K | $7.420M | $3.751M |
| YoY Change | 1779.65% | -1039.24% | 2698.98% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$1.472M | -$40.00K | -$2.079M |
| YoY Change | -83.16% | -233.33% | 42.02% |
| Pretax Income | -$9.420M | -$820.0K | -$8.503M |
| YoY Change | -36.48% | -87.94% | -67.64% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$6.313M | -$820.0K | -$18.20M |
| YoY Change | -57.44% | -87.94% | -31.1% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.23 | ||
| Diluted Earnings Per Share | -$7.030M | -$828.3K | -$0.79 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 94.60M | 36.40M | |
| Diluted Shares Outstanding | 37.09M |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q4 | 2018 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $7.380M | $15.54M | $15.54M |
| YoY Change | -52.42% | 94.71% | 94.74% |
| Cash & Equivalents | $308.7K | $1.628M | $15.54M |
| Short-Term Investments | $0.00 | $0.00 | |
| Other Short-Term Assets | $760.0K | $172.0K | $860.0K |
| YoY Change | -11.63% | 40.98% | 352.63% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $8.140M | $1.942M | $16.40M |
| YoY Change | -50.27% | -76.25% | 100.49% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $135.0K | $245.8K | $140.0K |
| YoY Change | -96.97% | -90.97% | -94.85% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $6.426M | $116.3K | $890.0K |
| YoY Change | 1160.0% | -16.91% | 535.71% |
| Total Long-Term Assets | $6.698M | $512.6K | $1.030M |
| YoY Change | 35.04% | -82.08% | -63.99% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $8.140M | $1.942M | $16.40M |
| Total Long-Term Assets | $6.698M | $512.6K | $1.030M |
| Total Assets | $14.84M | $2.454M | $17.43M |
| YoY Change | -30.44% | -77.76% | 57.88% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.100M | $3.278M | $1.590M |
| YoY Change | -19.12% | 322.36% | 103.85% |
| Accrued Expenses | $99.00K | $1.403M | $1.000M |
| YoY Change | -94.31% | -48.14% | -63.1% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $7.484M | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $0.00 | |
| YoY Change | -100.0% | -100.0% | |
| Total Short-Term Liabilities | $2.317M | $14.11M | $2.870M |
| YoY Change | -72.48% | 270.82% | -24.67% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $1.017M | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $18.05M | $37.46K | $15.01M |
| YoY Change | -45.27% | -99.8% | -18.86% |
| Total Long-Term Liabilities | $18.05M | $1.054M | $15.01M |
| YoY Change | -45.27% | -94.3% | -18.86% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.317M | $14.11M | $2.870M |
| Total Long-Term Liabilities | $18.05M | $1.054M | $15.01M |
| Total Liabilities | $20.37M | $15.16M | $17.89M |
| YoY Change | -50.8% | -32.01% | -19.78% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$226.2M | $31.24M | |
| YoY Change | -115.0% | ||
| Common Stock | $220.7M | $215.9M | |
| YoY Change | 9.64% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$18.61M | -$12.71M | -$460.0K |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $14.84M | $2.454M | $17.43M |
| YoY Change | -30.44% | -77.76% | 57.88% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q4 | 2018 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$6.313M | -$820.0K | -$18.20M |
| YoY Change | -57.44% | -87.94% | -31.1% |
| Depreciation, Depletion And Amortization | $14.60K | $90.00K | $49.62K |
| YoY Change | -91.51% | -74.29% | -96.77% |
| Cash From Operating Activities | -$2.667M | -$6.940M | -$11.63M |
| YoY Change | -181.17% | 60.65% | -49.48% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $10.58K | -$70.00K | $77.41K |
| YoY Change | -99.16% | -53.33% | -71.95% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $0.00 | $900.0K |
| YoY Change | -100.0% | -100.0% | -194.74% |
| Cash From Investing Activities | -$10.58K | -$70.00K | -$77.41K |
| YoY Change | -97.02% | -109.33% | -93.71% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $1.359M | 17.36M | $7.185M |
| YoY Change | -75.27% | -11673.33% | -1345.16% |
| NET CHANGE | |||
| Cash From Operating Activities | -$2.667M | -6.940M | -$11.63M |
| Cash From Investing Activities | -$10.58K | -70.00K | -$77.41K |
| Cash From Financing Activities | $1.359M | 17.36M | $7.185M |
| Net Change In Cash | -$1.319M | 10.35M | -$4.523M |
| YoY Change | -115.66% | -378.23% | -81.78% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.667M | -$6.940M | -$11.63M |
| Capital Expenditures | $10.58K | -$70.00K | $77.41K |
| Free Cash Flow | -$2.678M | -$6.870M | -$11.71M |
| YoY Change | -231.85% | 64.75% | -49.74% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3805000 | |
| CY2018Q4 | us-gaap |
Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
|
1125000 | |
| CY2017Q4 | us-gaap |
Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
|
3040000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
10000000 | |
| CY2018Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
351000 | |
| CY2017Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
280000 | |
| CY2018 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2018 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2018 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | |
| CY2018Q4 | us-gaap |
Incentive From Lessor
IncentiveFromLessor
|
1025000 | |
| CY2018 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2019Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
94599601 | |
| CY2017Q4 | us-gaap |
Incentive From Lessor
IncentiveFromLessor
|
499000 | |
| CY2018Q2 | dei |
Entity Public Float
EntityPublicFloat
|
63600000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15542000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
7081000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
900000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
858000 | |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
194000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
16400000 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
8175000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
141000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2723000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
750000 | |
| CY2018Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
137000 | |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
137000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
17428000 | |
| CY2017Q4 | us-gaap |
Deferred Revenue Leases Current
DeferredRevenueLeasesCurrent
|
111000 | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
11035000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1590000 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
776000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1000000 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2705000 | |
| CY2018Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
45000 | |
| CY2017Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
35000 | |
| CY2018Q4 | us-gaap |
Deferred Revenue Leases Current
DeferredRevenueLeasesCurrent
|
238000 | |
| CY2017Q4 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
178000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2873000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
24571029 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
62025398 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
24571029 | |
| CY2018Q4 | us-gaap |
Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
|
2512000 | |
| CY2017Q4 | us-gaap |
Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
|
14679000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
17886000 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
22303000 | |
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-458000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-11268000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
17428000 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11035000 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
62025398 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
513000 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
159000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
215859000 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
196760000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-216830000 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-208187000 | |
| CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
0 | |
| CY2017 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
0 | |
| CY2018 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
4270000 | |
| CY2018 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
163000 | |
| CY2017 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
134000 | |
| CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-106000 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-116000 | |
| CY2018 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
1540000 | |
| CY2018 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
733000 | |
| CY2018 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-20601000 | |
| CY2017 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1482000 | |
| CY2018 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
21465000 | |
| CY2017 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1464000 | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8643000 | |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26414000 | |
| CY2018 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8522000 | |
| CY2017 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-22499000 | |
| CY2018 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-29123000 | |
| CY2017 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-22499000 | |
| CY2018 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.23 | |
| CY2017 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.99 | |
| CY2018 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.79 | |
| CY2017 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.99 | |
| CY2018 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
36398450 | |
| CY2017 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22669819 | |
| CY2018 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37090197 | |
| CY2017 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22669819 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13567000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1573000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
6000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1625000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2000 | |
| CY2018 | hsgx |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
1000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
17825000 | |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-8643000 | |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-26414000 | |
| CY2018 | us-gaap |
Depreciation
Depreciation
|
450000 | |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
1534000 | |
| CY2017 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-54000 | |
| CY2018 | hsgx |
Deferred Revenue Non Cash Expense
DeferredRevenueNonCashExpense
|
10000000 | |
| CY2018 | hsgx |
Deferred Rent And Lease Incentive
DeferredRentAndLeaseIncentive
|
-734000 | |
| CY2017 | hsgx |
Deferred Rent And Lease Incentive
DeferredRentAndLeaseIncentive
|
543000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1625000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1573000 | |
| CY2018 | us-gaap |
Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
|
-4270000 | |
| CY2018 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
664000 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
21000 | |
| CY2018 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
750000 | |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
689000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-849000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
-360000 | |
| CY2018 | us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
-375000 | |
| CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1705000 | |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
524000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-15777000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-23020000 | |
| CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2013000 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
276000 | |
| CY2018 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
900000 | |
| CY2017 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
7050000 | |
| CY2017 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
8004000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1113000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1230000 | |
| CY2018 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
25526000 | |
| CY2018 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
178000 | |
| CY2017 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
583000 | |
| CY2018 | hsgx |
Proceeds From Exercise Of Stock Options And Warrants
ProceedsFromExerciseOfStockOptionsAndWarrants
|
3000 | |
| CY2017 | hsgx |
Proceeds From Exercise Of Stock Options And Warrants
ProceedsFromExerciseOfStockOptionsAndWarrants
|
6000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
25351000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-577000 | |
| CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
8461000 | |
| CY2017 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-24827000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
7218000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
32045000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
15679000 | |
| CY2018 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
125000 | |
| CY2018 | hsgx |
Public Offering Costs In Accounts Payable
PublicOfferingCostsInAccountsPayable
|
99000 | |
| CY2018 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
105000 | |
| CY2017 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
197000 | |
| CY2018 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1000 | |
| CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
30000 | |
| CY2018 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Organization</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Histogenics Corporation (the “Company”) was incorporated under the laws of the Commonwealth of Massachusetts on June 28, 2000 and has its principal operations in Waltham, Massachusetts. In 2006, the Company’s board of directors approved a corporate reorganization pursuant to which the Company incorporated as a Delaware corporation. The Company historically focused on the development of restorative cell therapies (RCTs). RCTs refer to a new class of products that are designed to offer patients rapid-onset pain relief and restored function through the repair of damaged or worn tissue. The Company’s lead product, NeoCart<sup style="font-size:85%; vertical-align:top">®</sup>, is an innovative cell therapy designed to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. In the third quarter of 2018, the Company announced that its Phase 3 clinical trial of NeoCart did not meet the primary endpoint in the Phase 3 clinical trial. Histogenics subsequently initiated a dialogue with the United States Food and Drug Administration (FDA) to discuss the regulatory path forward for NeoCart with a goal of determining whether the FDA would accept a submission of a Biologics License Application (BLA) for NeoCart without data from an additional Phase 3 clinical trial. In December 2018, the Company received final feedback from the FDA indicating the need for an additional Phase 3 clinical trial prior to the FDA’s acceptance of a NeoCart BLA submission. However, considering the time and funding required to conduct such a trial, the Company discontinued the development of NeoCart and is not planning to submit a BLA. In addition, the Company initiated a process to evaluate strategic alternatives to maximize value for all of its stakeholders. The process is being conducted with the assistance of financial and legal advisors and is evaluating the full range of potential strategic alternatives, including but not limited to, acquisitions, business combinations, joint ventures, public and private capital raises and recapitalization and sale transaction options, including a sale of assets or intellectual property. Since these efforts may not be successful and given our limited cash reserves, we are also considering other possible alternatives, including a wind-down of operations, or Chapter 11 bankruptcy protection to complete or execute a restructuring transaction or liquidation. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 13, 2011, the Company completed the acquisition of ProChon Biotech Ltd. (“ProChon”), a privately-held biotechnology company focused on modulating the fibroblast growth factor system for consideration of $2.2 million to enable it to create more effective solutions for tissue regeneration. ProChon’s products combine cell regeneration technologies with proprietary growth factors and biocompatible scaffolds to restore injured or chronically damaged tissues. The acquisition led to the initial recognition of goodwill, which was subsequently written off in 2011, and intangible assets including IPR&D and a licensing agreement which were fully impaired in 2016 as discussed in Note 2. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 29, 2016, the Company closed a private placement of common stock, preferred stock and warrants, contemplated by a securities purchase agreement dated September 15, 2016, with certain institutional and accredited investors. The net proceeds after deducting placement agent fees and other transaction-related expenses were $27.6 million. See Note 8, Capital Stock, for further discussion of the private placement. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the Company closed a registered direct offering where the Company issued 2,691,494 shares of<font style="font-weight:bold;"> </font>common stock at a price of $2.35 per share. The underwriter option to purchase additional shares of 351,064 were fully exercised. The total net proceeds of the offering were approximately $5.9 million after deducting underwriting discounts and commissions.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company entered into an equity distribution agreement (“ATM Agreement”) with Canaccord Genuity Inc. (“Canaccord”), pursuant to which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $10.0 million (the “Shares”) through Canaccord, as sales agent. During the year ended December 31, 2018, the Company sold an aggregate of 6,633,903 shares of common stock and received $4.5 million after deducting commissions related to the ATM Agreement and other offering costs. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2018, the Company closed an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The gross proceeds to Histogenics from this offering were $17.0 million, before deducting underwriting discounts and commissions, and offering expenses payable by the Company.  The warrants are exercisable immediately upon issuance at a price of $0.70 per share of common stock and have a term of five years commencing on the date of issuance. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its efforts to product development, recruiting management and technical staff, raising capital, starting up production and building infrastructure and has not yet generated product revenues. Expenses have primarily been for research and development and related administrative costs. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks including the successful development of therapeutics, the ability to obtain adequate financing, the ability to obtain FDA approval and reimbursement for any products we may develop, protection of intellectual property, fluctuations in operating results, dependence on key personnel and collaborative partners, rapid technological changes inherent in the target markets of any products the Company may develop, the introduction of substitute products and competition from larger companies. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company has incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit at December 31, 2018 of $216.8 million. The Company has financed operations to date primarily through public and private placements of equity securities, and borrowings under debt agreements. The Company anticipates that it will continue to incur net losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will only be sufficient to fund its projected cash needs into the middle of 2019. Accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. <font style="color:#000000;">To meet future capital needs, the Company would need to raise additional capital through debt or equity financing or other strategic transactions.</font> However, any such financing may not be on favorable terms or available to the Company.<font style="color:#000000;"> The failure of the Company to obtain sufficient funds on commercially acceptable terms when needed will have a material adverse effect on the Company’s business, results of operations and financial condition. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than it currently anticipates.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> | |
| CY2018 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards, warrant liability, recoverability of deferred tax assets, estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company recorded in 2018 a loss on impairment of fixed assets. See Note 5 Property and Equipment. The Company’s actual results may differ from these estimates under different assumptions or conditions. </p> | |
| CY2018 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss. </p> | |
| CY2018 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.75628 | |
| CY2017Q4 | hsgx |
Warrant Liability Fair Value
WarrantLiabilityFairValue
|
14679000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
0 | |
| CY2017 | us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
0 | |
| CY2018 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
2 | |
| CY2018 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2018Q4 | hsgx |
Fair Value Input Amount Transfer Between Levels
FairValueInputAmountTransferBetweenLevels
|
0 | |
| CY2017Q4 | hsgx |
Fair Value Input Amount Transfer Between Levels
FairValueInputAmountTransferBetweenLevels
|
0 | |
| CY2018Q4 | hsgx |
Money Market Funds Fair Value
MoneyMarketFundsFairValue
|
9711000 | |
| CY2018Q4 | hsgx |
Warrant Liability Fair Value
WarrantLiabilityFairValue
|
2512000 | |
| CY2017Q4 | hsgx |
Money Market Funds Fair Value
MoneyMarketFundsFairValue
|
5547000 | |
| CY2017Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
900000 | |
| CY2018 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
0 | |
| CY2018Q4 | hsgx |
Percentage Of Stock Price Decreased
PercentageOfStockPriceDecreased
|
0.73 | |
| CY2018Q4 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
10000000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1892000 | |
| CY2018 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
9.97 | |
| CY2018 | hsgx |
Maximum Percentage Of Recognition Of Tax Benefits From Uncertain Tax Positions
MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions
|
0.50 | |
| CY2018 | hsgx |
Net Income Loss Available To Series A Preferred Stock
NetIncomeLossAvailableToSeriesAPreferredStock
|
121000 | |
| CY2017 | hsgx |
Net Income Loss Available To Series A Preferred Stock
NetIncomeLossAvailableToSeriesAPreferredStock
|
3915000 | |
| CY2018 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
-20601000 | |
| CY2018 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
691747 | |
| CY2018Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
686000 | |
| CY2017Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
72000 | |
| CY2018Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
172000 | |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
122000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
10427000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13642000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
10286000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
10919000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
514000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1671000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
159000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
133000 | |
| CY2018Q4 | hsgx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
90000 | |
| CY2017Q4 | hsgx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
70000 | |
| CY2018Q4 | hsgx |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
86000 | |
| CY2017Q4 | hsgx |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
199000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
151000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
632000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1845000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
1941000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1991000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
1728000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
1460000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
10857000 | |
| CY2018 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1600000 | |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1000000 | |
| CY2018 | hsgx |
Beneficial Ownership Minimum Percentage Of Outstanding Common Stock
BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock
|
0.50 | |
| CY2018Q4 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
8400000 | |
| CY2018Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
36484699 | |
| CY2017Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
15791418 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
30000 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
2.25 | |
| CY2016Q3 | hsgx |
Minimum Threshold Percentage Of Beneficial Common Stock Interest
MinimumThresholdPercentageOfBeneficialCommonStockInterest
|
0.0499 | |
| CY2016Q3 | hsgx |
Maximum Threshold Percentage Of Beneficial Common Stock Interest On Holders Discretion
MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion
|
0.0999 | |
| CY2018 | us-gaap |
Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
|
The Series A Preferred Stock shall not be converted if, after giving effect to the conversion, the holder and its affiliated persons would own beneficially more than 4.99% of our common stock (subject to adjustment up to 9.99% solely at the holder’s discretion upon 61 days’ prior notice to us or, solely as to a holder, if such limitation is waived by such holder upon execution of the private placement agreement). | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2158348 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
4311090 | |
| CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
919 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
3129048 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3339471 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
3314542 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1603725 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.40 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.21 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.56 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.60 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.03 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
1.03 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1.37 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M6D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M6D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y1M6D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y1M6D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
436000 | |
| CY2018Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
2300000 | |
| CY2017Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
1400000 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
8000 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
0.76 | |
| CY2018Q4 | hsgx |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
|
0.52 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.59 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.02 | |
| CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1625000 | |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1573000 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0284 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0203 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.844 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.629 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y3M21D | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y29D | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
| CY2018 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
|
0.0257 | |
| CY2017 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
|
0.0129 | |
| CY2018 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
|
0.883 | |
| CY2017 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
|
0.623 | |
| CY2018 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
|
P6Y29D | |
| CY2017 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
|
P6Y29D | |
| CY2018 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
|
0.000 | |
| CY2017 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
|
0.000 | |
| CY2018Q4 | hsgx |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
|
0.568 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-8503000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-26275000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-140000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-140000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-8643000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-26415000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.211 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.337 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.225 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.000 | |
| CY2018 | hsgx |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
0.544 | |
| CY2018 | hsgx |
Effective Income Tax Rate Reconciliation Net Operating Loss Limitation
EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation
|
0.000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.00 | |
| CY2018 | hsgx |
Effective Income Tax Rate Reconciliation R And D Credit Limitation
EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation
|
0.009 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.985 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.004 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
24941000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
4878000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
141000 | |
| CY2018Q4 | hsgx |
Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
|
9143000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
312000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1155000 | |
| CY2018 | hsgx |
Tax Cuts And Jobs Act Of2017 Limitation Of Net Operating Loss Deduction Percentage Of Annual Taxable Income
TaxCutsAndJobsActOf2017LimitationOfNetOperatingLossDeductionPercentageOfAnnualTaxableIncome
|
0.80 | |
| CY2018 | hsgx |
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
|
0 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
303000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2017Q4 | us-gaap |
Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
|
0 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
562000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
|
0 | |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
|
123000 | |
| CY2018 | hsgx |
Unrecognized Tax Benefits Federal Rate Revision
UnrecognizedTaxBenefitsFederalRateRevision
|
0 | |
| CY2017 | hsgx |
Unrecognized Tax Benefits Federal Rate Revision
UnrecognizedTaxBenefitsFederalRateRevision
|
136000 | |
| CY2018Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
303000 | |
| CY2018Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
| CY2018 | us-gaap |
Income Tax Examination Description
IncomeTaxExaminationDescription
|
The Company is subject to U.S. federal, state and local income tax examinations by tax authorities for years 2001 through present. Carryforward attributes that were generated in earlier periods remain subject to examination to the extent the year in which they were used or will be used remains open for examination. The tax years which remain subject to examination by tax authorities in Israel, as of December 31, 2018, include years 2014 through the present. | |
| CY2018 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 |
